Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
Self-reported levels of awareness, knowledge and behaviour varied considerably by HCP type and among patient respondents. Further investigation is needed into why certain measures of the pregnancy prevention programme are not well known and followed, to improve their effectiveness. This will be addressed in a qualitative study which will be based on interviews with HCPs and patients.
Authors
- Massoud Toussi (ORCID: https://orcid.org/0000-0001-6780-0676)
- T Nishikawa (ORCID: https://orcid.org/0009-0006-8754-1417)
- Marie‐Laure Kürzinger (ORCID: https://orcid.org/0000-0002-2606-776X)
- Sandrine Colas
- I. Dresco (ORCID: https://orcid.org/0000-0002-9837-040X)
- K. Marinier (ORCID: https://orcid.org/0000-0002-8715-2220)
- Sigal Kaplan (ORCID: https://orcid.org/0000-0002-3352-8480)
- Aude Lachacinski (ORCID: https://orcid.org/0009-0002-2019-9144)
Institutions
- Sanofi (France) (FR)
- Sanofi (Canada) (CA)
- Teva Pharmaceuticals (Israel) (IL)
- IQVIA (France) (FR)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/pds.70046
- Citations
- 2
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.22
Funders
- Sanofi
- Teva Pharmaceutical Industries
- Hexal AG
- Mylan
- G.L. Pharma
- Neuraxpharm
- Wockhardt
- Desitin Arzneimittel